Survival benefit in advanced or metastatic breast cancer with visceral metastases

June 12, 2020

Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.

The findings are from a subgroup analysis of the phase 3 MONALESSA-3 and MONALEESA-7 trials and were presented during the ASCO20 Virtual Scientific Program.

Learn more and read the full article from Drug Topics.